Hengrui is reshaping cancer care in China with a suite of new medicines that target the most common and deadly tumors. In breast cancer, the company’s drug Pyrotinib has become a new standard for HER2‑positive patients, while Dalpiclib now pushes the average time before disease progression past 30 months for advanced hormone‑responsive tumors. A next‑generation antibody‑drug conjugate, Trastuzumab Deruxtecan, recently showed patients could stay progression‑free for more than 30 months in second‑line therapy, a record in its class. For liver cancer, Hengrui’s “dual‑AI” combo of an immune checkpoint inhibitor (Camrelizumab) and a blood‑vessel blocker (Apatinib) delivered a median overall survival of nearly two years in the first‑line setting, the longest seen with similar treatments. Early‑stage liver cancer patients also benefited, with a new study reporting a clear jump in event‑free survival after surgery when the same regimen was used. In gastric cancer, the company introduced the world’s first PD‑L1/TGF‑β bispecific antibody, Relafulimab Alpha, giving doctors a brand‑new weapon for advanced disease. Beyond tumor‑killing drugs, Hengrui rolled out supportive‑care products that tame chemotherapy‑induced nausea, protect blood counts, and help patients maintain quality of life. Finally, new medical‑insurance policies are ensuring these innovations reach patients faster and more affordably, turning scientific breakthroughs into real‑world health gains for China’s population.
Read more